NeRRe Therapeutics Announces Appointment of Ian Nicholson as Chief Bus
NeRRe Therapeutics Ltd, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, is pleased to announce the appointment of Ian Nicholson as Chief Business Officer (CBO). Ian brings with him over 25 years’ international experience within the life sciences sector, covering both management and transactions and will be responsible for driving NeRRe’s business development strategy and providing commercial input into the company’s programmes. He will continue in his role of CEO of F2G Limited and as an Operating Partner of Advent Life Sciences LLP. His extensive experience of licensing, M&A, and global market development comes via a variety of senior positions with Chroma Therapeutics, Celltech, Oxford Asymmetry, Lonza AG and Amersham International.
Dr Mike Trower, Chief Operating Officer of NeRRe Therapeutics, said “I am delighted that an individual of Ian’s calibre has joined the leadership team of NeRRe Therapeutics as CBO. Ian’s significant experience in the biotech industry and of partnering makes him a great addition to our team at this important stage of the company’s development. I am excited about working closely with him to evaluate the considerable business opportunities that our portfolio offers.”
For more information about NeRRe Therapeutics, please contact:
Dr Mike Trower, Chief Operating Officer (COO)
Tel: +44 (0) 1438 906960
Email: info@nerretherapeutics.com
About NeRRe Therapeutics
NeRRe Therapeutics was formed in December 2012 and is focussed on the development of a portfolio of NK receptor antagonists acquired from GlaxoSmithKline (GSK), which have therapeutic potential in a broad range of indications. Dr Mike Trower (Company Co-founder and COO) is a former executive from neurosciences drug discovery at GSK with intimate knowledge of the transferred assets and the neurokinin receptor system field. In 2012 NeRRe Therapeutics raised £11.5 million ($18.4 million) in Series A financing from two leading European financial institutions, Novo A/S (www.novo.dk/ventures) and Advent Life Sciences (www.adventventures.com), who are represented by Dr Martin Edwards (Chairman) and Dr Kaasim Mahmood respectively on the company’s Board.
NeRRe (www.nerretherapeutics.com) is based at the state-of-the-art Stevenage Bioscience Catalyst (www.stevenagecatalyst.com), the UK’s first open innovation bioscience campus.
